Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials

INTRODUCTION: Controversy regarding optimum duration of trastuzumab treatment remains in patients with human epidermal growth factor receptor-2 (HER2) positive early breast cancer. The objective of applying network meta-analysis (NMA) is to integrate existing evidence based on direct and indirect co...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Qiancheng, Wang, Xin, Chen, Ye, Li, Xiaofen, Luo, Ting, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682472/
https://www.ncbi.nlm.nih.gov/pubmed/33444169
http://dx.doi.org/10.1136/bmjopen-2019-035802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682472/
https://www.ncbi.nlm.nih.gov/pubmed/33444169
http://dx.doi.org/10.1136/bmjopen-2019-035802

Ejemplares similares